FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205503977> ?p ?o ?g. }

• W4205503977 endingPage "TPS7" @default.
• W4205503977 startingPage "TPS7" @default.
• W4205503977 abstract "TPS7 Background: Even though the recurrence rate remains high, chemoradiotherapy (CRT) alone is the standard treatment in locally advanced squamous cell anal carcinoma (SCAC), in the absence of effective neoadjuvant/adjuvant treatment. Modified docetaxel, cisplatin and 5FU (mDCF) is one of the standard regimens in metastatic SCAC, and induced a radiological complete response (cCR) in 45% of patients, with a biological CR (the conversion from positive to negative HPV ctDNA by liquid biopsy) in 61% of patients. Among chemotherapy-naïve patients, the cCR was as high as 55%, with 90% of ORR and 100% of disease control rate during the first 4 months. Moreover, mDCF was associated with a decrease in Myeloid-Derived Suppressive Cells (MDSC) and an increase in the antitumor anti-hTERT immunity, two major factors correlated with prognosis in advanced SCAC, rendering mDCF a good partner to combine with immunotherapy. Anti-PD1 immunotherapy is effective in chemorefractory SCAC. In sensitive tumors, neoadjuvant anti-PD1, with or without chemotherapy, induced a high rate (30-45%) of complete or near-complete pathological response. The combination of mDCF and immunotherapy is safe. Methods: INTERACTION is an open-label, pivotal, single arm, phase II study in neoadjuvant setting for stage 3 SCAC patients (NCT04719988). Fifty-five patients will receive up to 6 cycles of mDCF (docetaxel 40 mg/m 2 and cisplatin 40 mg/m 2 on day 1, 5-fluorouracil 2400 mg/m 2 over 46 h) every 2 weeks, in association with ezabenlimab (anti-PD1 mAb) at 240 mg every 3 weeks. CT-scan, MRI, tumor and liquid biopsies will be performed before treatment, and after 4 cycles. CRT will be start after cycle 6. Then, ezabenlimab will be administered in the adjuvant setting up to 10 months from cycle 1. Eligible candidates include patients with treatment-naïve histologically proven locally advanced SCAC, an ECOG PS of 0 or 1, and age ≥18 years. The primary endpoint is the clinical complete response rate at 10 months from the first cycle of mDCF plus ezabenlimab. Main secondary endpoints are the major pathological response (complete/near-complete response) and biological CR (HPV ctDNA negative) after induction treatment. Other secondary endpoints include the ORR, OS, PFS, RFS, HRQoL and safety. An extensive ancillary study will be performed to predict response or resistance to treatment. Peiffert D et al. JCO 2012;30:1941–8; James RD et al. Lancet Oncol 2013;14:516–24; Kim S et al. Lancet Oncol 2018; 19:1094–106; Kim S et al. TAMO 2020;12:1758835920975356; Spehner L et al. IJMS 2020;21:6838; Ott PA et al. Ann Oncol 2017;28:1036–41; Morris VK et al. Lancet Oncol 2017;18:446–53; Huang AC et al. Nat Med 2019;25:454–61; Necchi A et al. JCO 2018;36:3353–60; Forde PM et al. NEJM 2018;378:1976–86; Kim S et al. BMC Cancer 2020;20:352. Clinical trial information: EudraCT 2020-006046-40 and Clinicaltrials.gov NCT04719988." @default.
• W4205503977 created "2022-01-26" @default.
• W4205503977 creator A5005521442 @default.
• W4205503977 creator A5010700417 @default.
• W4205503977 creator A5013525685 @default.
• W4205503977 creator A5014323516 @default.
• W4205503977 creator A5022288769 @default.
• W4205503977 creator A5026121059 @default.
• W4205503977 creator A5038199519 @default.
• W4205503977 creator A5038856629 @default.
• W4205503977 creator A5042306519 @default.
• W4205503977 creator A5043463827 @default.
• W4205503977 creator A5052299853 @default.
• W4205503977 creator A5056483951 @default.
• W4205503977 creator A5060536774 @default.
• W4205503977 creator A5063565613 @default.
• W4205503977 creator A5075690105 @default.
• W4205503977 creator A5077000250 @default.
• W4205503977 creator A5081839591 @default.
• W4205503977 date "2022-02-01" @default.
• W4205503977 modified "2023-10-17" @default.
• W4205503977 title "Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma: INTERACTION phase II study." @default.
• W4205503977 doi "https://doi.org/10.1200/jco.2022.40.4_suppl.tps7" @default.
• W4205503977 hasPublicationYear "2022" @default.
• W4205503977 type Work @default.
• W4205503977 citedByCount "0" @default.
• W4205503977 crossrefType "journal-article" @default.
• W4205503977 hasAuthorship W4205503977A5005521442 @default.
• W4205503977 hasAuthorship W4205503977A5010700417 @default.
• W4205503977 hasAuthorship W4205503977A5013525685 @default.
• W4205503977 hasAuthorship W4205503977A5014323516 @default.
• W4205503977 hasAuthorship W4205503977A5022288769 @default.
• W4205503977 hasAuthorship W4205503977A5026121059 @default.
• W4205503977 hasAuthorship W4205503977A5038199519 @default.
• W4205503977 hasAuthorship W4205503977A5038856629 @default.
• W4205503977 hasAuthorship W4205503977A5042306519 @default.
• W4205503977 hasAuthorship W4205503977A5043463827 @default.
• W4205503977 hasAuthorship W4205503977A5052299853 @default.
• W4205503977 hasAuthorship W4205503977A5056483951 @default.
• W4205503977 hasAuthorship W4205503977A5060536774 @default.
• W4205503977 hasAuthorship W4205503977A5063565613 @default.
• W4205503977 hasAuthorship W4205503977A5075690105 @default.
• W4205503977 hasAuthorship W4205503977A5077000250 @default.
• W4205503977 hasAuthorship W4205503977A5081839591 @default.
• W4205503977 hasConcept C121608353 @default.
• W4205503977 hasConcept C126322002 @default.
• W4205503977 hasConcept C141071460 @default.
• W4205503977 hasConcept C143998085 @default.
• W4205503977 hasConcept C2776694085 @default.
• W4205503977 hasConcept C2777863537 @default.
• W4205503977 hasConcept C2777909004 @default.
• W4205503977 hasConcept C2778239845 @default.
• W4205503977 hasConcept C2780456651 @default.
• W4205503977 hasConcept C2781190966 @default.
• W4205503977 hasConcept C31760486 @default.
• W4205503977 hasConcept C526805850 @default.
• W4205503977 hasConcept C71924100 @default.
• W4205503977 hasConceptScore W4205503977C121608353 @default.
• W4205503977 hasConceptScore W4205503977C126322002 @default.
• W4205503977 hasConceptScore W4205503977C141071460 @default.
• W4205503977 hasConceptScore W4205503977C143998085 @default.
• W4205503977 hasConceptScore W4205503977C2776694085 @default.
• W4205503977 hasConceptScore W4205503977C2777863537 @default.
• W4205503977 hasConceptScore W4205503977C2777909004 @default.
• W4205503977 hasConceptScore W4205503977C2778239845 @default.
• W4205503977 hasConceptScore W4205503977C2780456651 @default.
• W4205503977 hasConceptScore W4205503977C2781190966 @default.
• W4205503977 hasConceptScore W4205503977C31760486 @default.
• W4205503977 hasConceptScore W4205503977C526805850 @default.
• W4205503977 hasConceptScore W4205503977C71924100 @default.
• W4205503977 hasIssue "4_suppl" @default.
• W4205503977 hasLocation W42055039771 @default.
• W4205503977 hasOpenAccess W4205503977 @default.
• W4205503977 hasPrimaryLocation W42055039771 @default.
• W4205503977 hasRelatedWork W1571712 @default.
• W4205503977 hasRelatedWork W2293350 @default.
• W4205503977 hasRelatedWork W2942244 @default.
• W4205503977 hasRelatedWork W3184125 @default.
• W4205503977 hasRelatedWork W3269070 @default.
• W4205503977 hasRelatedWork W3582852 @default.
• W4205503977 hasRelatedWork W4287607 @default.
• W4205503977 hasRelatedWork W4408631 @default.
• W4205503977 hasRelatedWork W5038423 @default.
• W4205503977 hasRelatedWork W3109140 @default.
• W4205503977 hasVolume "40" @default.
• W4205503977 isParatext "false" @default.
• W4205503977 isRetracted "false" @default.
• W4205503977 workType "article" @default.